Clinical Trials Logo

Neuromyelitis Optica clinical trials

View clinical trials related to Neuromyelitis Optica.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06413654 Not yet recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorders

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Start date: June 20, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.

NCT ID: NCT06398158 Not yet recruiting - Clinical trials for Neuromyelitis Optica

Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder

AMAZE
Start date: June 1, 2024
Phase:
Study type: Observational

This is an observational study to: - evaluate the on-treatment clinical performance of ravulizumab in relation to the pre-treatment time period (time period prior to exposure), - enhance knowledge regarding conventional MRI outcomes in people with NMOSD treated with ravulizumab, - identify factors suggestive of subclinical disease progression through conventional MRI sequences, - determine if treatment with ravulizumab, impacts longitudinal 3D conformational MRI measures at the dorsal medulla and other regions of the CNS, and - identify biomarkers (e.g., serum neurofilament light chain (sNfL), conventional and novel MRI markers, etc.) related to disease activity.

NCT ID: NCT06374264 Not yet recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorder

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

aNiMatO
Start date: June 15, 2024
Phase: N/A
Study type: Interventional

The purpose of this proof of concept study is to assess the acceptability and safety of MR-C-014 in persons with Neuromyelitis optica spectrum disorder (NMOSD) who have a gait deficit.

NCT ID: NCT06312644 Not yet recruiting - Pregnancy Clinical Trials

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Start date: March 29, 2024
Phase:
Study type: Observational [Patient Registry]

The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.

NCT ID: NCT06280755 Not yet recruiting - Multiple Sclerosis Clinical Trials

Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.

RECLAIM
Start date: March 2024
Phase:
Study type: Observational

The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to develop the tools to monitor this progression.

NCT ID: NCT06212245 Not yet recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorders

A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Start date: February 25, 2024
Phase: Phase 4
Study type: Interventional

To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.

NCT ID: NCT06118398 Not yet recruiting - Clinical trials for Neuromyelitis Optica

Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders

Start date: November 5, 2023
Phase:
Study type: Observational

This study aims to retrospective investigate the safety and effectiveness of Efgartigimod in the acute phase of neuromyelitis optica spectrum disorders (NMOSD) patients.

NCT ID: NCT06068829 Not yet recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorders

Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

Start date: October 20, 2023
Phase:
Study type: Observational

To compare the safety and efficacy of Inebilizumab and Rituximab in neuromyelitis optica spectrum disorders (NMOSD) patients.

NCT ID: NCT05974293 Not yet recruiting - Spasticity, Muscle Clinical Trials

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

SENS-NMO
Start date: April 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and efficacy of nabiximols, a cannabinoid spray, for the treatment of moderate to severe spasticity in adult patients with AQP4-IgG positive and antibody-negative NMOSD. The main question it aims to answer is whether treatment with nabiximols improves patient-reported spasticity ratings compared to treatment with a placebo. This trial will also answer whether nabiximols impact pain, spasm frequency, mood, walking ability, and sleep. Participants will be mailed the treatments and placebo treatments, and will be asked to complete study visits and questionnaires remotely. There is also an optional sub-study that involves in-person visits with ultrasound imaging and in-person neurologic exams.

NCT ID: NCT05891379 Not yet recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorder

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders

Start date: July 20, 2023
Phase:
Study type: Observational

This study is aimed to observe the effectiveness and safety of inebilizumab in the acute phase of neuromyelitis optica spectrum disorders.